文献速递淋巴瘤

通过差异激酶抑制靶向慢性淋巴细胞白血病中的抗原非依赖性增殖

Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
PubMed 文献 · Leukemia · 2017-05-02

本研究探讨临床应用的B细胞受体(BCR)信号通路抑制剂对慢性淋巴细胞白血病(CLL)细胞抗原非依赖性增殖的影响。CD40L/IL-21诱导的增殖可被艾德拉尼和伊布替尼抑制,机制为阻断CD40L诱导的ERK信号;抑制JAK而非SYK可阻断该增殖。相反,PI3K、BTK及SYK抑制可阻止CpG诱导的增殖。数据表明当前BTK/PI3K抑制剂靶向抗原非依赖性增殖,靶向JAK和/或SYK可能具有临床价值。

要点

  • CD40L/IL-21诱导的CLL增殖可被艾德拉尼和伊布替尼抑制,源于阻断CD40L诱导的ERK信号。
  • 抑制JAK而非SYK可阻断CD40L/IL-21诱导的增殖。
  • PI3K、BTK及SYK抑制可阻止CpG诱导的增殖。

核心结论

  • 目前应用的BTK/PI3K抑制剂靶向CLL中的抗原非依赖性增殖。
  • 靶向JAK和/或SYK可能具有临床价值。

研究设计与样本

  • 体外研究,探讨临床应用的BCR信号通路抑制剂对CD40L/IL-21或CpG刺激触发的CLL细胞增殖的影响。

主要发现

  • CD40L/IL-21诱导的增殖可被艾德拉尼和伊布替尼抑制,机制为阻断CD40L诱导的ERK信号。
  • 抑制JAK而非SYK可阻断CD40L/IL-21诱导的增殖。
  • PI3K、BTK及SYK抑制可阻止CpG诱导的增殖。
  • 敲低实验显示CD40L/IL-21不利用CD79A等上游BCR组分,而CpG诱导的增殖则利用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical success of B-cell receptor (BCR) signaling pathway inhibitors in chronic lymphocytic leukemia (CLL) is attributed to inhibition of adhesion in and migration towards the lymph node. Proliferation of CLL cells is restricted to this protective niche, but the underlying mechanism(s) is/are not known. Treatment with BCR pathway inhibitors results in rapid reductions of total clone size, while CLL cell survival is not affected, which points towards inhibition of proliferation. In vitro, BCR stimulation does not induce proliferation of CLL, but triggering via Toll-like receptor, tumor necrosis factor or cytokine receptors does. Here, we investigated the effects of clinically applied inhibitors that target BCR signaling, in the context of proliferation triggered either via CD40L/IL-21 or after CpG stimulation. CD40L/IL-21-induced proliferation could be inhibited by idelalisib and ibrutinib. We demonstrate this was due to blockade of CD40L-induced ERK-signaling. Targeting JAKs, but not SYK, blocked CD40L/IL-21-induced proliferation. In contrast, PI3K, BTK as well as SYK inhibition prevented CpG-induced proliferation. Knockdown experiments showed that CD40L/IL-21 did not co-opt upstream BCR components such as CD79A, in contrast to CpG-induced proliferation. Our data indicate that currently applied BTK/PI3K inhibitors target antigen-independent proliferation in CLL, and suggest that targeting of JAK and/or SYK might be clinically useful.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Slinger E, Thijssen R, Kater AP, et al. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia. 2017. PMID: 28462919. doi:10.1038/leu.2017.129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。